Japan-Drug Eluting Stents Evaluation; a Randomized Trial

Inclusion Criteria: * Patient is ≥ 20 years old * Patient suitable for percutaneous coronary intervention (PCI) * Patient with signed informed consent * Patient judged suitable to receive anti-platelet drugs (clopidogrel bisulfate or ticlopidine hydrochloride, etc.) in principle for at least 6 months after procedure, and ideally up to 12 months in patients who are not at high risk of bleeding, based on ACC/AHA guideline * Patient with up to 3 lesions (with ≥ 50% of stenosis) in the maximum of 2 targeted vessels to be treated at once * Patient with reference vessel diameter (RVD) of 2.5 mm to 3.75 mm by visual observation * Patient with length of each lesion of up to 46 mm by visual assessment * Patient eligible for implementation of drug eluting stent. Exclusion Criteria: * Patient with any planned treatment in the targeted vessel with a drug eluting stent other than in this study * Patient with acute myocardial infarction (AMI) (including non-ST segment elevation MI) developed within 7 days before the procedure * Patient participating in a currently ongoing registry or clinical study, or receiving a treatment which may affect the endpoints of this study * Patient of childbearing potential with a positive pregnancy test within 14 days before the procedure, or lactating * Patient who has history of allergy against Sirolimus, Paclitaxel, polymers or stainless steel * Patient who has history of side-effect against anti-platelet drugs or anti-coagulation drugs * Patient with serious hepatic dysfunction * Patient with left ventriculogram ejection fraction of 35% or less * Patient with three target vessels in need of PCI treatment * Patient with serious renal dysfunction (serum creatinine value 2mg/dL or higher) * Patient currently receiving artificial dialysis * Patient with a malignant tumor (cancer) diagnosed within 5 years before the procedure * Patient who has received PCI treatment within the past one year * Patient with chronic total occlusion (CTO) or TIMI flow 2 or less * Patient with \>50% stenosis in left main coronary artery * Patient with \>50% stenosis in side branch ostial for which stenting in the side branch lesion is required (KBT for side branch is accepted) * Patient with in-stent restenosis in the target lesion implanted with a bare-metal or drug eluting stent * Patient who has target lesion in saphenous vein graft * Patient judged non-eligible by the physician in charge.